← Back to all trials
Not Yet Recruiting
NCT07752550
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
Conditions: Triple-Negative Breast Cancer (TNBC)
Sex: Female
Ages: 18 Years – 100 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 120
Sponsor: Harbin Medical University
Location: Harbin Medical University Cancer Hospital Harbin Heilongjiang
Summary
To investigate the efficacy and safety of Retlirafusp alfa in combination with chemotherapy or fluzoparib for early-stage and advanced triple-negative breast cancer.
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years, female;
2. Histopathologically confirmed recurrent or metastatic triple-negative breast cancer, defined as ER-negative (IHC ER-positive percentage \
Source: ClinicalTrials.gov (NCT07752550). StuddyBuddy aggregates publicly available trial information.
